Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
new option listings and one option delisting on May 5th » 08:30
05/05/21
05/05
08:30
05/05/21
08:30
AIQ

Alliance HealthCare

$28.51 /

-0.66 (-2.26%)

, ASEA

Aegean Sea

$14.66 /

-0.185 (-1.25%)

, BTX

Brooklyn ImmunoTherapeutics

$54.73 /

-21.32 (-28.03%)

, CIGI

Colliers International

$115.70 /

+6.09 (+5.56%)

, DOOO

BRP Inc.

$90.90 /

-1.6 (-1.73%)

, EDR

Endeavor

$29.99 /

-0.785 (-2.55%)

, ELDN

Eledon Pharmaceuticals

$9.85 /

-0.05 (-0.51%)

, FLUX

Flux Power

$10.44 /

-0.505 (-4.61%)

, FSV

FirstService

$159.97 /

-2.31 (-1.42%)

, GWRS

Global Water Resources

$16.50 /

-0.67 (-3.90%)

, MYMD

MyMD Pharmaceuticals

$4.20 /

-0.01 (-0.24%)

, NEBC

Nebula Caravel Acquisition

$9.90 /

+ (+0.00%)

, SLGL

Sol-Gel Technologies

$10.51 /

-0.19 (-1.78%)

, TARA

Protara Therapeutics

$10.43 /

-0.76 (-6.79%)

, VRCA

Verrica Pharmaceuticals

$12.27 /

-0.08 (-0.65%)

New option listings for…

New option listings for May 5th include Global X Funds Global X Future Analytics Tech ETF (AIQ), Global X SuperDividend Alternatives (ALTY), Global X Southeast Asia (ASEA), Aspirational Consumer Lifestyle Corp (Class A Stock) (ASPL), Brooklyn ImmunoTherapeutics Inc (BTX), Global X MSCI China Information Technology ETF (CHIK), Colliers International (CIGI), BRP Inc (DOOO), Endeavor Group Holdings Inc (Class A Stock) (EDR), Eledon Pharmaceuticals Inc (ELDN), Fidelity Momentum Factor ETF (FDMO), Fidelity Dividend ETF for Rising Rates (FDRR), Fidelity Core Dividend ETF (FDVV), Fidelity International High Dividend ETF (FIDI), Flux Power Holdings Inc (FLUX), Fidelity Quality Factor ETF (FQAL), Fidelity Small Mid Multifactor ETF (FSMD), FirstService (FSV), Fidelity Value Factor ETF (FVAL), Global Water Resources (GWRS), Global X Thematic Growth ETF (GXTG), Direxion Daily S&P 500 High Beta Bull 3x Shares (HIBL), Global X Conscious Companies (KRMA), Global X Millennials Thematic (MILN), MyMD Pharmaceuticals Inc (MYMD), Nebula Caravel Acquisition Corporation (Class A Stock) (NEBC), Fidelity Nasdaq Composite Index (ONEQ), First Trust Nasdaq Artificial Intelligence and Robotics (ROBT), Global X SuperDividend Emerging Markets ETF (SDEM), Sol Gel Technologies Ltd (SLGL), SVF Investment Corporation (Class A Stock) (SVFA), Protara Therapeutics Inc (TARA), Verrica Parmaceuticals Inc (VRCA), Direxion Daily Consumer Discretionary Bull 3x Shares (WANT), Direxion Daily Dow Jones Internet Bull 3x Shares (WEBL), and Global X S&P 500 Covered Call ETF (XYLD). Option delistings effective May 5th include Valaris Plc (VALPQ).

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

AIQ Alliance HealthCare
$28.51 /

-0.66 (-2.26%)

ASEA Aegean Sea
$14.66 /

-0.185 (-1.25%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

02/16/21 TD Securities
Colliers International price target raised to $125 from $100 at TD Securities
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
02/16/21 RBC Capital
Colliers International price target raised to $126 from $96 at RBC Capital
01/25/21
Fly Intel: Top five analyst initiations
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

04/26/21 Citi
BRP Inc. initiated with a Buy at Citi
04/06/21 Stifel
BRP Inc. downgraded to Hold from Buy at Stifel
03/29/21 Desjardins
BRP Inc. price target raised to C$131 from C$107 at Desjardins
03/26/21 CIBC
BRP Inc. price target raised to C$117 from C$100 at CIBC
EDR Endeavor
$29.99 /

-0.785 (-2.55%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/22/21 Cantor Fitzgerald
Eledon Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
02/08/21 SVB Leerink
SVB Leerink bullish on Eledon Pharmaceuticals, initiates with an Outperform
FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21
Flux Power initiated with a Buy at Maxim
10/12/20 Roth Capital
Flux Power initiated with a Buy at Roth Capital
FSV FirstService
$159.97 /

-2.31 (-1.42%)

04/28/21 Raymond James
Raymond James downgrades FirstService to Market Perform on 'healthy valuation'
04/28/21 Raymond James
FirstService downgraded to Market Perform from Outperform at Raymond James
04/28/21
Fly Intel: Top five analyst downgrades
04/28/21 TD Securities
FirstService downgraded to Hold from Buy at TD Securities
GWRS Global Water Resources
$16.50 /

-0.67 (-3.90%)

02/25/21 Roth Capital
Global Water Resources price target raised to $19 from $12.50 at Roth Capital
MYMD MyMD Pharmaceuticals
$4.20 /

-0.01 (-0.24%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

04/09/21
Fly Intel: Top five analyst initiations
04/09/21 Tigress Financial
Nebula Caravel Acquisition initiated with a Buy at Tigress Financial
03/19/21
Fly Intel: Top five analyst initiations
03/19/21 DA Davidson
Rover initiated with a Buy at DA Davidson amid COVID-related tailwinds
SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
10/19/20 Cowen
Protara Therapeutics initiated with an Outperform at Cowen
07/29/20
Fly Intel: Top five analyst initiations
07/29/20 Guggenheim
Protara Therapeutics started with Buy rating, $50 target at Guggenheim
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

TARA Protara Therapeutics
$10.43 /

-0.76 (-6.79%)

SLGL Sol-Gel Technologies
$10.51 /

-0.19 (-1.78%)

FSV FirstService
$159.97 /

-2.31 (-1.42%)

FLUX Flux Power
$10.44 /

-0.505 (-4.61%)

ELDN Eledon Pharmaceuticals
$9.85 /

-0.05 (-0.51%)

CIGI Colliers International
$115.70 /

+6.09 (+5.56%)

  • 29
    Apr
  • 23
    Mar
  • 22
    Sep
DOOO BRP Inc.
$90.90 /

-1.6 (-1.73%)

VRCA Verrica Pharmaceuticals
$12.27 /

-0.08 (-0.65%)

NEBC Nebula Caravel Acquisition
$9.90 /

+ (+0.00%)

EDR Endeavor
$29.99 /

-0.785 (-2.55%)

BTX Brooklyn ImmunoTherapeutics
$54.73 /

-21.32 (-28.03%)

Over a week ago
Hot Stocks
Sol-Gel Technologies says action on EPSOLAY NDA could not be taken » 10:05
04/27/21
04/27
10:05
04/27/21
10:05
SLGL

Sol-Gel Technologies

$12.61 /

-1.09 (-7.96%)

Sol-Gel Technologies…

Sol-Gel Technologies announced an update regarding the U.S. Food and Drug Administration approval process for EPSOLAY 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for EPSOLAY is April 26, 2021. Subsequently, the COVID-19 pandemic restricted the FDA's ability to conduct pre-approval inspections. In our most recent written communication with the FDA regarding EPSOLAY, the final content of the labeling was discussed and agreed to. As of today, Sol-Gel has received no notification from the FDA, but did receive email confirmation that that action on the NDA for EPSOLAY could not be taken since a pre-approval inspection of the production site of EPSOLAY still needs to be conducted. The Company continues to follow-up with the FDA on the scheduling of this inspection.

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$12.61 /

-1.09 (-7.96%)

SLGL Sol-Gel Technologies
$12.61 /

-1.09 (-7.96%)

Conference/Events
FDA PDUFA Date for Sol-Gel Technologies Epsolay is April 26, 2021  08:48
04/26/21
04/26
08:48
04/26/21
08:48
SLGL

Sol-Gel Technologies

$14.20 /

+0.02 (+0.14%)

 
ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$14.20 /

+0.02 (+0.14%)

SLGL Sol-Gel Technologies
$14.20 /

+0.02 (+0.14%)

Over a month ago
Hot Stocks
Sol-Gel Technologies expects cash to fund requirements into 3Q22 » 07:20
03/04/21
03/04
07:20
03/04/21
07:20
SLGL

Sol-Gel Technologies

$9.58 /

-0.05 (-0.52%)

As of December 31, 2020,…

As of December 31, 2020, Sol-Gel had $28.5 million in cash, cash equivalents and deposits, and $21.7 million in marketable securities for a total balance of $50.2 million. Sol-Gel expects its existing cash resources will enable funding of operational and capital expenditure requirements into the third quarter of 2022.

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

Earnings
Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) » 07:19
03/04/21
03/04
07:19
03/04/21
07:19
SLGL

Sol-Gel Technologies

$9.58 /

-0.05 (-0.52%)

Reports 2020 revenue…

Reports 2020 revenue $8.8M, consensus $8.3M. "I am very pleased with the major milestones that were achieved by Sol-Gel last year. After announcing positive data from Phase 3 trials of Epsolay and Twyneo and submitting NDAs to the FDA within guided timelines, 2020 was highlighted by positive acceptances of both NDAs and allocated PDUFA dates," commented Dr. Alon Seri-Levy, Chief Executive Officer of Sol-Gel. "Given the competitive landscape of the dermatology market and the significant capital that would be needed to directly commercialize our products, our current operational model assumes we will partner with a dermatology company that has a strong market presence. This would enable us to capture market share more quickly without the need to invest in building our own marketing and sales force and would allow us to further invest in the development of our pipeline of products with larger potential markets," continued Dr. Seri-Levy.

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

Over a quarter ago
Hot Stocks
Sol-Gel Technologies announces FDA acceptance of NDA filing for Twyneo » 07:15
12/07/20
12/07
07:15
12/07/20
07:15
SLGL

Sol-Gel Technologies

$9.36 /

+0.23 (+2.52%)

Sol-Gel Technologies…

Sol-Gel Technologies announced that its New Drug Application for Twyneo, an investigational proprietary fixed-dose combination of 3% encapsulated benzoyl peroxide and 0.1% encapsulated tretinoin cream for the treatment of acne vulgaris, has been accepted for filing by the U.S. Food and Drug Administration. The Prescription Drug User Fee Act goal date assigned by the FDA for Twyneo is August 1, 2021. The NDA filing is based on two positive pivotal Phase 3 randomized, double-blind, multicenter, 12-week, clinical trials that evaluated the safety and efficacy of Twyneo compared to vehicle in patients 9 years of age and older with moderate-to-severe acne vulgaris. In both trials, Twyneo demonstrated statistically significant improvement in all co-primary endpoints in the treatment of patients with acne vulgaris of the proportion of patients who succeeded in achieving at least a two grade reduction from baseline and Clear or Almost Clear at Week 12 on a 5-point Investigator Global Assessment scale, an absolute change from baseline in inflammatory lesion count at Week 12 and an absolute change from baseline in non-inflammatory lesion count at Week 12. The most common adverse events were local reactions, such as pain, dryness, exfoliation, erythema, dermatitis, pruritus and irritation, with nearly all adverse events being mild or moderate in severity and no treatment-related serious AEs.

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$9.36 /

+0.23 (+2.52%)

SLGL Sol-Gel Technologies
$9.36 /

+0.23 (+2.52%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
SLGL Sol-Gel Technologies
$9.36 /

+0.23 (+2.52%)

SLGL Sol-Gel Technologies
$9.36 /

+0.23 (+2.52%)

Hot Stocks
Sol-Gel Technologies expects cash to fund operations into 3Q21 » 07:19
11/12/20
11/12
07:19
11/12/20
07:19
SLGL

Sol-Gel Technologies

$8.50 /

+0.53 (+6.65%)

As of September 30, 2020,…

As of September 30, 2020, Sol-Gel had $27.4 million in cash, cash equivalents and deposits, and $29.9 million in marketable securities for a total balance of $57.3 million. Sol-Gel expects its existing cash resources will enable funding of operational and capital expenditure requirements into the third quarter of 2021.

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

Earnings
Sol-Gel Technologies reports Q3 EPS (37c), consensus (46c) » 07:19
11/12/20
11/12
07:19
11/12/20
07:19
SLGL

Sol-Gel Technologies

$8.50 /

+0.53 (+6.65%)

Reports Q3 revenue $2.1M,…

Reports Q3 revenue $2.1M, consensus $1.82M. "The third quarter was highlighted by a major achievement for Sol-Gel, as our first New Drug Application for Epsolay for the treatment of inflammatory lesions of rosacea was accepted by the Federal Drug Administration with a Prescription Drug User Fee Act goal date set for April 26, 2021. We now look forward to the NDA acceptance of our second proprietary product, Twyneo, for the treatment of acne vulgaris," commented Dr. Alon Seri-Levy, CEO of Sol-Gel. "Also, after the close of the third quarter, we expanded our collaboration with Perrigo to develop an eleventh generic product candidate. While we are successfully expanding our partnership with Perrigo, we continue to focus on our own branded product candidates, Epsolay and Twyneo. We are working towards commercializing both treatments, if approved, in 2021, either on our own or with a partner that has a significant U.S. dermatology presence."

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

SLGL Sol-Gel Technologies
$8.50 /

+0.53 (+6.65%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/17/20
09/17
04:55
09/17/20
04:55
ACRS

Aclaris Therapeutics

$2.40 /

+0.05 (+2.13%)

, AUTL

Autolus Therapeutics

$14.03 /

+0.25 (+1.81%)

, EIGR

Eiger BioPharmaceuticals

$10.07 /

+0.13 (+1.31%)

, INO

Inovio

$18.52 /

+4.89 (+35.88%)

, KALA

Kala Pharmaceuticals

$8.61 /

+0.56 (+6.96%)

, OVID

Ovid Therapeutics

$6.61 /

+0.2 (+3.12%)

, PAVM

PAVmed

$1.89 /

+0.01 (+0.53%)

, SLGL

Sol-Gel Technologies

$7.69 /

+0.22 (+2.95%)

, VNRX

VolitionRx

$3.20 /

+0.015 (+0.47%)

, XFOR

X4 Pharmaceuticals

$7.31 /

+0.25 (+3.54%)

, XNCR

Xencor

$41.53 /

+0.66 (+1.61%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$41.53 /

+0.66 (+1.61%)

XFOR X4 Pharmaceuticals
$7.31 /

+0.25 (+3.54%)

VNRX VolitionRx
$3.20 /

+0.015 (+0.47%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

AUTL Autolus Therapeutics
$14.03 /

+0.25 (+1.81%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$18.52 /

+4.89 (+35.88%)

XNCR Xencor
$41.53 /

+0.66 (+1.61%)

SLGL Sol-Gel Technologies
$7.69 /

+0.22 (+2.95%)

PAVM PAVmed
$1.89 /

+0.01 (+0.53%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

EIGR Eiger BioPharmaceuticals
$10.07 /

+0.13 (+1.31%)

ACRS Aclaris Therapeutics
$2.40 /

+0.05 (+2.13%)

OVID Ovid Therapeutics
$6.61 /

+0.2 (+3.12%)

KALA Kala Pharmaceuticals
$8.61 /

+0.56 (+6.96%)

INO Inovio
$18.52 /

+4.89 (+35.88%)

Conference/Events
Cantor Fitzgerald to hold a virtual conference » 04:55
09/16/20
09/16
04:55
09/16/20
04:55
ACRS

Aclaris Therapeutics

$2.35 /

+0.135 (+6.09%)

, AUTL

Autolus Therapeutics

$13.78 /

-0.01 (-0.07%)

, EIGR

Eiger BioPharmaceuticals

$9.93 /

-0.21 (-2.07%)

, INO

Inovio

$13.63 /

+2.3 (+20.30%)

, KALA

Kala Pharmaceuticals

$8.04 /

+0.05 (+0.63%)

, OVID

Ovid Therapeutics

$6.41 /

+0.17 (+2.72%)

, PAVM

PAVmed

$1.88 /

+0.055 (+3.01%)

, SLGL

Sol-Gel Technologies

$7.47 /

+0.02 (+0.27%)

, VNRX

VolitionRx

$3.18 /

-0.05 (-1.55%)

, XFOR

X4 Pharmaceuticals

$7.09 /

-0.05 (-0.70%)

, XNCR

Xencor

$40.87 /

+0.66 (+1.64%)

Virtual Global Healthcare…

Virtual Global Healthcare Conference will be held on September 15-17.

ShowHide Related Items >><<
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform at SVB Leerink
10/22/19 SVB Leerink
Aclaris Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
10/11/19 William Blair
William Blair sees 'significant value disconnect' in Aclaris Therapeutics
AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

09/09/20 Benchmark
Inovio LOI 'effectively puts to bed' doubts about manufacturing, says Benchmark
08/11/20 Stifel
Inovio price target lowered to $16 from $24 at Stifel
08/11/20 Cantor Fitzgerald
Inovio price target lowered to $31 from $45 at Cantor Fitzgerald
08/11/20 Roth Capital
Roth Capital keeps Sell rating on Inovio, doesn't see COVID vaccine as contender
KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

09/14/20
Fly Intel: Top five analyst downgrades
09/14/20 Jefferies
Jefferies downgrades Kala to Hold, cuts target to $10 following physician survey
09/14/20 Jefferies
Kala Pharmaceuticals downgraded to Hold from Buy at Jefferies
08/28/20 Wedbush
Kala Pharmaceuticals removed from Best Ideas List at Wedbush
OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

08/26/20 Cantor Fitzgerald
Ovid Therapeutics price target lowered to $12 from $13 at Cantor Fitzgerald
08/26/20 RBC Capital
Ovid Therapeutics price target raised to $17 from $13 at RBC Capital
08/26/20 Citi
Ovid Therapeutics price target raised to $10 from $9 at Citi
07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
03/26/20 Citi
X4 Pharmaceuticals an attractive buy trading near cash, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
02/13/20 Roth Capital
X4 patent strengthens commercial outlook for mavorixafor, says Roth
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$40.87 /

+0.66 (+1.64%)

XFOR X4 Pharmaceuticals
$7.09 /

-0.05 (-0.70%)

VNRX VolitionRx
$3.18 /

-0.05 (-1.55%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

AUTL Autolus Therapeutics
$13.78 /

-0.01 (-0.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

  • 25
    Aug
  • 20
    May
  • 11
    Mar
  • 23
    Jan
  • 26
    Nov
  • 04
    Oct
INO Inovio
$13.63 /

+2.3 (+20.30%)

XNCR Xencor
$40.87 /

+0.66 (+1.64%)

SLGL Sol-Gel Technologies
$7.47 /

+0.02 (+0.27%)

PAVM PAVmed
$1.88 /

+0.055 (+3.01%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

EIGR Eiger BioPharmaceuticals
$9.93 /

-0.21 (-2.07%)

ACRS Aclaris Therapeutics
$2.35 /

+0.135 (+6.09%)

OVID Ovid Therapeutics
$6.41 /

+0.17 (+2.72%)

KALA Kala Pharmaceuticals
$8.04 /

+0.05 (+0.63%)

INO Inovio
$13.63 /

+2.3 (+20.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.